FDA approves Eli Lilly diabetes drug
Tirzepatide, a treatment for type 2 diabetes developed by Eli Lilly, has been approved by the FDA, setting the stage for a direct competition with Novo Nordisk’s Ozempic.
by marketwire, translated by daniel pedersen
On Friday, US-based pharmaceutical firm Eli Lilly could announce that the US Food and Drug Administration (FDA) has approved tirzepatide for patients with type 2 diabetes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly wants to gain on Novo Nordisk's obesity lead
For subscribers
